Ignite Creation Date:
2024-05-06 @ 8:14 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06305494
Status:
RECRUITING
Last Update Posted:
2024-04-25
First Post:
2024-03-03
Brief Title:
Genitourinary Syndrome of Menopause in Thai Gynecologic Cancer Survivors
Sponsor:
Khon Kaen University
Organization:
Khon Kaen University
Study Overview
Official Title:
Genitourinary Syndrome of Menopause in Thai Gynecologic Cancer Survivors A Cross-sectional Study
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Women often face common cancers like ovarian uterine and cervical cancers Improvements in cancer detection and treatment mean more women survive However survivors can encounter challenges like ongoing pain treatment complications and fertility issues
Treating these cancers often involves surgeries that might include removing ovaries or using pelvic radiation This can trigger menopause in younger women causing problems like vaginal dryness itching and urinary issues
Women whove gone through menopause often deal with these symptoms affecting their daily lives confidence and intimate relationships Though treatments are available lack of awareness embarrassment and not discussing these issues with doctors can make managing them difficult
The main treatment for these symptoms is using vaginal estrogen but it might not be suitable for some cancer survivors Non-hormonal options like lubricants and moisturizers are alternatives This study in Thailand aiming to explore how common these issues are among gynecological cancer survivors their feelings about it and how it affects their quality of life
Treating these cancers often involves surgeries that might include removing ovaries or using pelvic radiation This can trigger menopause in younger women causing problems like vaginal dryness itching and urinary issues
Women whove gone through menopause often deal with these symptoms affecting their daily lives confidence and intimate relationships Though treatments are available lack of awareness embarrassment and not discussing these issues with doctors can make managing them difficult
The main treatment for these symptoms is using vaginal estrogen but it might not be suitable for some cancer survivors Non-hormonal options like lubricants and moisturizers are alternatives This study in Thailand aiming to explore how common these issues are among gynecological cancer survivors their feelings about it and how it affects their quality of life
Detailed Description:
Gynecological cancers encompassing ovarian endometrial and cervical cancers stand as significant health concerns for women In 2017 a total of 12354 new cases were diagnosed in Thailand underlining the prevalence and impact of these conditions Advances in cancer screening and treatment have notably improved outcomes resulting in a growing number of survivors By 2016 the United States alone recorded 155 million cancer survivors with projections indicating a surge to 261 million by 2040 However even with increased survival rates challenges persist for survivors encompassing chronic pain complications from treatment and disruptions to fertility menopause sexual function and cognitive health
The treatment landscape for gynecological cancers is diverse with the general principle for ovarian and endometrial cancers involving surgical staging This comprehensive approach includes the removal of the uterus fallopian tubes both ovaries peritoneum pelvic lymph nodes and any visible lesions For cervical cancer treatment varies based on disease stage Early-stage cases often undergo surgery potentially followed by pelvic irradiation In advanced-stage cervical cancer a combination of pelvic radiation and chemotherapy is commonly employed In summary many gynecological cancer treatments involve the removal of both ovaries or pelvic irradiation inducing menopause in reproductive-age women
The female lower reproductive system including the lower urinary tract is intricately responsive to estrogenic stimulation When estrogen is lacking structural changes occur giving rise to a cluster of symptoms collectively termed the genitourinary syndrome of menopause GSM Estrogen deficiency results in thinning of the vaginal epithelium lining diminished collagen and elastin fibers reduced blood supply and moisture decline These changes manifest as vaginal symptoms including burning itching and pain during intercourse
Similarly the urinary tract deprived of estrogenic stimulation undergoes alterations such as urethral shortening thinning of the urethral epithelium weakened urethral sphincter contractions and reduced elasticity of the urinary bladder This cascade of changes results in lower urinary tract symptoms comprising dysuria urinary urgency incontinence frequency nocturia and recurrent urinary tract infections
Postmenopausal women commonly experience these symptoms and systematic literature reviews reveal a prevalence ranging from 13 to 87 Furthermore the chronic nature of these symptoms tends to intensify over time Women who undergo early bilateral oophorectomy are more likely to enter menopause sooner increasing the risk of developing various urogenital symptoms at a younger age
The impact of these symptoms on womens lives is profound affecting daily activities self-confidence and intimate relationships Vaginal symptoms in particular can lead to sexual dysfunction exacerbating challenges in family relationships Concurrently urinary symptoms contribute to decreased quality of life with frequency nocturia and urgency correlating with the risk of falls and bone fractures Additionally these symptoms are associated with depressed mood anxiety and embarrassment further disrupting aspects of life such as sleep daily commute social interactions and sexual relationships
Despite the significant impact on quality of life the effective management of vaginal and genitourinary symptoms is impeded by various factors These include a lack of knowledge and understanding of the diseases and available treatment options feelings of embarrassment and the notable observation that medical personnel often fail to inquire about these specific issues during patient consultations
The primary treatment for genitourinary symptoms is typically the use of vaginal estrogen However certain gynecological cancers such as leiomyosarcoma endometrial stromal sarcoma and specific ovarian cancers preclude the use of estrogen therapy In such cases non-hormonal alternatives like vaginal lubricants moisturizers and energy-based devices come into consideration
This study aim to explore the prevalence of GSM among gynecological cancer survivors The investigation extends to understanding the magnitude of the problem examining womens attitudes towards the condition and assessing its broader impact on their quality of life This comprehensive exploration seeks to contribute valuable insights to the understanding and management of the complex challenges faced by gynecological cancer survivors
The treatment landscape for gynecological cancers is diverse with the general principle for ovarian and endometrial cancers involving surgical staging This comprehensive approach includes the removal of the uterus fallopian tubes both ovaries peritoneum pelvic lymph nodes and any visible lesions For cervical cancer treatment varies based on disease stage Early-stage cases often undergo surgery potentially followed by pelvic irradiation In advanced-stage cervical cancer a combination of pelvic radiation and chemotherapy is commonly employed In summary many gynecological cancer treatments involve the removal of both ovaries or pelvic irradiation inducing menopause in reproductive-age women
The female lower reproductive system including the lower urinary tract is intricately responsive to estrogenic stimulation When estrogen is lacking structural changes occur giving rise to a cluster of symptoms collectively termed the genitourinary syndrome of menopause GSM Estrogen deficiency results in thinning of the vaginal epithelium lining diminished collagen and elastin fibers reduced blood supply and moisture decline These changes manifest as vaginal symptoms including burning itching and pain during intercourse
Similarly the urinary tract deprived of estrogenic stimulation undergoes alterations such as urethral shortening thinning of the urethral epithelium weakened urethral sphincter contractions and reduced elasticity of the urinary bladder This cascade of changes results in lower urinary tract symptoms comprising dysuria urinary urgency incontinence frequency nocturia and recurrent urinary tract infections
Postmenopausal women commonly experience these symptoms and systematic literature reviews reveal a prevalence ranging from 13 to 87 Furthermore the chronic nature of these symptoms tends to intensify over time Women who undergo early bilateral oophorectomy are more likely to enter menopause sooner increasing the risk of developing various urogenital symptoms at a younger age
The impact of these symptoms on womens lives is profound affecting daily activities self-confidence and intimate relationships Vaginal symptoms in particular can lead to sexual dysfunction exacerbating challenges in family relationships Concurrently urinary symptoms contribute to decreased quality of life with frequency nocturia and urgency correlating with the risk of falls and bone fractures Additionally these symptoms are associated with depressed mood anxiety and embarrassment further disrupting aspects of life such as sleep daily commute social interactions and sexual relationships
Despite the significant impact on quality of life the effective management of vaginal and genitourinary symptoms is impeded by various factors These include a lack of knowledge and understanding of the diseases and available treatment options feelings of embarrassment and the notable observation that medical personnel often fail to inquire about these specific issues during patient consultations
The primary treatment for genitourinary symptoms is typically the use of vaginal estrogen However certain gynecological cancers such as leiomyosarcoma endometrial stromal sarcoma and specific ovarian cancers preclude the use of estrogen therapy In such cases non-hormonal alternatives like vaginal lubricants moisturizers and energy-based devices come into consideration
This study aim to explore the prevalence of GSM among gynecological cancer survivors The investigation extends to understanding the magnitude of the problem examining womens attitudes towards the condition and assessing its broader impact on their quality of life This comprehensive exploration seeks to contribute valuable insights to the understanding and management of the complex challenges faced by gynecological cancer survivors
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None